These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Karantanos T; Evans CP; Tombal B; Thompson TC; Montironi R; Isaacs WB Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226 [TBL] [Abstract][Full Text] [Related]
5. Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer. Yang YC; Banuelos CA; Mawji NR; Wang J; Kato M; Haile S; McEwan IJ; Plymate S; Sadar MD Clin Cancer Res; 2016 Sep; 22(17):4466-77. PubMed ID: 27140928 [TBL] [Abstract][Full Text] [Related]
6. Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence. Coutinho I; Day TK; Tilley WD; Selth LA Endocr Relat Cancer; 2016 Dec; 23(12):T179-T197. PubMed ID: 27799360 [TBL] [Abstract][Full Text] [Related]
7. Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer. Welti J; Rodrigues DN; Sharp A; Sun S; Lorente D; Riisnaes R; Figueiredo I; Zafeiriou Z; Rescigno P; de Bono JS; Plymate SR Eur Urol; 2016 Oct; 70(4):599-608. PubMed ID: 27117751 [TBL] [Abstract][Full Text] [Related]
8. ASC-J9(®) suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L. Wang R; Lin W; Lin C; Li L; Sun Y; Chang C Cancer Lett; 2016 Aug; 379(1):154-60. PubMed ID: 27233475 [TBL] [Abstract][Full Text] [Related]
9. [New generation of androgen receptor antagonist in castration resistant prostate cancer]. Uemura H Nihon Rinsho; 2014 Dec; 72(12):2164-9. PubMed ID: 25518352 [TBL] [Abstract][Full Text] [Related]
10. Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Shafi AA; Yen AE; Weigel NL Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952 [TBL] [Abstract][Full Text] [Related]
11. [Inhibitors of the androgen receptor N‑terminal domain : Therapies targeting the Achilles' heel of various androgen receptor molecules in advanced prostate cancer]. Hupe MC; Offermann A; Perabo F; Chandhasin C; Perner S; Merseburger AS; Cronauer MV Urologe A; 2018 Feb; 57(2):148-154. PubMed ID: 29147733 [TBL] [Abstract][Full Text] [Related]
12. Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns. De Laere B; van Dam PJ; Whitington T; Mayrhofer M; Diaz EH; Van den Eynden G; Vandebroek J; Del-Favero J; Van Laere S; Dirix L; Grönberg H; Lindberg J Eur Urol; 2017 Aug; 72(2):192-200. PubMed ID: 28104311 [TBL] [Abstract][Full Text] [Related]
13. Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer. Schalken J; Fitzpatrick JM BJU Int; 2016 Feb; 117(2):215-25. PubMed ID: 25818596 [TBL] [Abstract][Full Text] [Related]
14. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. Del Re M; Biasco E; Crucitta S; Derosa L; Rofi E; Orlandini C; Miccoli M; Galli L; Falcone A; Jenster GW; van Schaik RH; Danesi R Eur Urol; 2017 Apr; 71(4):680-687. PubMed ID: 27733296 [TBL] [Abstract][Full Text] [Related]
15. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer. Thamilselvan V; Menon M; Thamilselvan S Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552 [TBL] [Abstract][Full Text] [Related]
16. Lessons from in-vivo models of castration-resistant prostate cancer. Lin D; Gout PW; Wang Y Curr Opin Urol; 2013 May; 23(3):214-9. PubMed ID: 23385975 [TBL] [Abstract][Full Text] [Related]
17. TAS3681, an androgen receptor antagonist, prevents drug resistance driven by aberrant androgen receptor signaling in prostate cancer. Yoshida S; Kajiwara D; Seki M; Tayama M; Tanaka Y; Mizutani H; Fujita R; Yamamura K; Okajima S; Asai M; Minamiguchi K Mol Oncol; 2024 Aug; 18(8):1980-2000. PubMed ID: 38600681 [TBL] [Abstract][Full Text] [Related]
18. SC912 inhibits AR-V7 activity in castration-resistant prostate cancer by targeting the androgen receptor N-terminal domain. Yi Q; Han X; Yu HG; Chen HY; Qiu D; Su J; Lin R; Batist G; Wu JH Oncogene; 2024 May; 43(20):1522-1533. PubMed ID: 38532114 [TBL] [Abstract][Full Text] [Related]
19. Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Castration-resistant Prostate Cancer with Next generation Androgen Receptor Signal Inhibition: A Systematic Review and Meta-analysis. Li H; Wang Z; Tang K; Zhou H; Liu H; Yan L; Guan W; Chen K; Xu H; Ye Z Eur Urol Focus; 2018 Jul; 4(4):529-539. PubMed ID: 28753843 [TBL] [Abstract][Full Text] [Related]
20. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer. Bernemann C; Schnoeller TJ; Luedeke M; Steinestel K; Boegemann M; Schrader AJ; Steinestel J Eur Urol; 2017 Jan; 71(1):1-3. PubMed ID: 27471164 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]